Effects of the abrupt switch from solution to modified-release granule formulation of valproate

Acta Neurologica Scandinavica

Volumn 125, Issue 3, 2012, Pages

  Verrotti, A ^a   Nanni, G ^a   Agostinelli, S ^a   Alleva, E T ^b   Aloisi, P ^b   Franzoni, E ^c   Spalice, A ^d   Chiarelli, F ^a   Coppola, G ^e  

^a UNIVERSITY OF CHIETI   (Italy)

^b UNIVERSITY OF L'AQUILA   (Italy)

^c UNIVERSITY OF BOLOGNA   (Italy)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

^e SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

Compliance; Efficacy; Epilepsy; Modified release formulation; Palatability; Tolerability; Valproate

Indexed keywords

VALPROIC ACID;

AGGRESSIVENESS; CHILD; CLINICAL TRIAL; DIARRHEA; DROWSINESS; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ERUPTION; DRUG FORMULATION; DRUG GRANULE; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; ELECTROENCEPHALOGRAM; EPILEPSY; FEMALE; FOLLOW UP; HAIR LOSS; HUMAN; INCREASED APPETITE; LEARNING DISORDER; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA AND VOMITING; NOTE; PALATABILITY; PATIENT COMPLIANCE; PRESCHOOL CHILD; RESTLESSNESS; SCHOOL CHILD; SIDE EFFECT; TREMOR;

ANTICONVULSANTS; CHEMISTRY, PHARMACEUTICAL; CHILD; CHILD, PRESCHOOL; DELAYED-ACTION PREPARATIONS; EPILEPSY; FEMALE; HUMANS; MALE; PROSPECTIVE STUDIES; VALPROIC ACID;

EID: 84856710209     PISSN: 00016314     EISSN: 16000404     Source Type: Journal    
DOI: 10.1111/j.1600-0404.2011.01568.x     Document Type: Note

References (15)

1. Guerrini R. Valproate as a mainstay of therapy for pediatric epilepsy. Paediatr Drugs 2006;8:113-29.
2. Doughty J, Baker GA, Jacoby A, Lavaud V. Compliance and satisfaction with switching from an immediate-release to sustained-release formulation of valproate in people with epilepsy. Epilepsy Behav 2003;4:710-6.
3. Pellock JM, Smith MC, Cloyd JC, Uthman B, Wilder BJ. Extended-release formulations: simplifying strategies in the management of antiepileptic drug therapy. Epilepsy Behav 2004;5:301-7.
4. Genton P. Progress in pharmaceutical development presentation with improved pharmacokinetics: a new formulation for valproate. Acta Neurol Scand Suppl 2005;182:26-32.
5. Dulac O, Alvarez JC. Bioequivalence of a new sustained-release formulation of sodium valproate, valproate modified-release granules, compared with existing sustained-release formulations after once- or twice-daily administration. Pharmacotherapy 2005;25:35-41.
6. Motte J, Pedespan JM, Sevestre M, Chiron C; Groupe AME. Acceptability and tolerance of sodium valproate, a new sustained-action granule formulation, in monotherapy for epileptic children from 3years old (in French). Arch Pediatr 2005;12:1533-9.
7. Powers JL, Gooch WM III, Oddo LP. Comparison of the palatability of the oral suspension of cefdinir vs. amoxicillin/clavulanate potassium, cefprozil and azithromycin in pediatric patients. Pediatr Infect Dis J 2000;19:S174-80.
8. Cohen R, De La Rocque F, Lécuyer A, Wollner C, Bodin MJ, Wollner A. Study of the acceptability of antibiotic syrups, suspensions, and oral solutions prescribed to pediatric outpatients. Eur J Pediatr 2009;168:851-7.
9. Martínez JM, Bartoli F, Recaldini E, Lavanchy L, Bianchetti MG. A taste comparison of two different liquid colecalciferol (vitamin D3) preparations in healthy newborns and infants. Clin Drug Investig 2006;26:663-5.
10. Dolezal C, Mellins C, Brackis-Cott E, Abrams EJ. The reliability of reports of medical adherence from children with HIV and their adult caregivers. J Pediatr Psychol 2003;28:355-61.
11. Nunn T, Williams J. Formulation of medicines for children. Br J Clin Pharmacol 2005;59:674-6.
12. WHO. Make Medicines child size. Available at: (Last accessed 10 December, 2010).
13. Bhosle M, Benner JS, Dekoven M, Shelton J. Difficult to swallow: patient preferences for alternative VPA pharmaceutical formulations. Patient Prefer Adherence 2009;3:161-71.
14. Winnick S, Lucas DO, Hartman AL, Toll D. How do you improve compliance? Pediatrics 2005;115:e718-24.
15. Cramer JA, Glassman M, Rienzi V. The relationship between poor medication compliance and seizures. Epilepsy Behav 2002;3:338-42.